{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:37:20Z","timestamp":1791463040956,"version":"4.3.4"},"reference-count":173,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>M184V is a single-base mutation in the YMDD domain of reverse transcriptase (RT). The M184V resistance-associated mutation (RAM) is related to virological unresponsiveness to lamivudine (3TC) and emtricitabine (FTC) and induces high-level resistance to these two antiretroviral agents. M184V is rapidly selected in the setting of non-suppressive antiretroviral therapy (ART) and accumulates in the HIV reservoir. There were continuous efforts to evaluate the impact of the M184V mutation on the treatment outcomes in people living with HIV (PLWH). Since 3TC remains an extensively used part of recommended antiretroviral combinations, M184V is commonly detected in patients with virological failure (VF). ART guidelines do not recommend the use of drugs impacted by RAMs as they have been confirmed to comprise a risk factor for VF. However, there is evidence that 3TC\/FTC can remain active even in the presence of M184V. Given the potential benefits of 3TC in ART combinations, the investigation of M184V remains of high interest to clinicians and researchers, especially in certain regions with limited resources, and especially for its unusual effects. This is a review of the literature on the challenges in treating both na\u00efve and experienced individuals carrying the M184V mutation, including virological failure, virological suppression, and resistance to ART.<\/jats:p>","DOI":"10.3390\/v16091392","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T10:54:11Z","timestamp":1725015251000},"page":"1392","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment Management Challenges in Na\u00efve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation"],"prefix":"10.3390","volume":"16","author":[{"given":"Iordanis","family":"Mimtsoudis","sequence":"first","affiliation":[{"name":"Infectious Diseases Division 1st Internal Medicine Department, AHEPA University Hospital Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Tsachouridou","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division 1st Internal Medicine Department, AHEPA University Hospital Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-9494","authenticated-orcid":false,"given":"Karolina","family":"Akinosoglou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symeon","family":"Metallidis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division 1st Internal Medicine Department, AHEPA University Hospital Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, February 10). HIV\/AIDS. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Johnson, M.M., Jones, C.E., and Clark, D.N. (2022). The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles. Viruses, 15.","DOI":"10.3390\/v15010107"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3851\/IMP3331","article-title":"Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review","volume":"24","author":"Vannappagari","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/jac\/dkx042","article-title":"Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies\/mL: A 2014 French nationwide study","volume":"72","author":"Assoumou","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Meriki, H.D., Tufon, K.A., Anong, D.N., Atanga, P.N., Anyangwe, I.A., Cho-Ngwa, F., and Nkuo-Akenji, T. (2019). Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225575"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100238","DOI":"10.1016\/j.eclinm.2019.100238","article-title":"Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001\u20132017)","volume":"18","author":"Zuo","year":"2020","journal-title":"eClinicalMedicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12981-017-0161-z","article-title":"High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa","volume":"14","author":"Etta","year":"2017","journal-title":"AIDS Res. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1545109711421217","article-title":"Resistance-Associated Mutations in HIV-1 among Patients Failing First-Line Antiretroviral Therapy","volume":"11","author":"Saini","year":"2011","journal-title":"J. Int. Assoc. Physicians AIDS Care"},{"key":"ref_9","first-page":"556","article-title":"The M184V Mutation: What It Does, How to Prevent It, and What to Do with It When It\u2019s There","volume":"16","author":"Gallant","year":"2006","journal-title":"AIDS Reader"},{"key":"ref_10","unstructured":"European AIDS Clinical Society (2024, February 12). EACS Guidelines 12.0. Available online: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/jac\/dkae007","article-title":"Use of genotypic HIV DNA testing: A DELPHI-type consensus","volume":"79","author":"Bocket","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Peng, Y., Zong, Y., Wang, D., Chen, J., Chen, Z.-S., Peng, F., and Liu, Z. (2023). Current drugs for HIV-1: From challenges to potential in HIV\/AIDS. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1294966"},{"key":"ref_13","first-page":"1","article-title":"The management of treatment-experienced HIV patients (including virologic failure and switches)","volume":"7","author":"Cutrell","year":"2020","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jclinepi.2022.02.005","article-title":"Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis","volume":"148","author":"Hauser","year":"2022","journal-title":"J. Clin. Epidemiol."},{"key":"ref_15","unstructured":"(2017). EPIVIR-HBV [Package Insert, GlaxoSmithKline."},{"key":"ref_16","unstructured":"World Health Organization (2015). Serum and Red Blood Cell Folate Concentrations for Assessing Folate Status in Populations, Vitamin and Mineral Nutrition Information System. Available online: http:\/\/apps.who.int\/iris\/bitstream\/10665\/162114\/1\/WHO_NMH_NHD_EPG_15.01.pdf?ua=1."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the International Antiviral Society\u2013USA Panel","volume":"316","author":"Saag","year":"2016","journal-title":"JAMA"},{"key":"ref_18","unstructured":"European AIDS Clinical Society (2018, January 31). Guidelines, Version 9.0. Available online: http:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf."},{"key":"ref_19","unstructured":"Panel for Antiretroviral Guidelines for Adults and Adolescents (2023, April 26). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/archive\/AdultandAdolescentGL_2021_08_16.pdf."},{"key":"ref_20","unstructured":"Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children (2024, February 18). Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, Available online: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/pediatric-arv\/guidelines-pediatric-arv.pdf."},{"key":"ref_21","unstructured":"Panel on Treatment of HIV during Pregnancy and Prevention of Perinatal Transmission (2024, May 12). Recommendations for the Use of Antiretroviral Drugs during Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586310\/bin\/pregnancyguide.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/AAC.35.7.1386","article-title":"Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2\u2032-deoxy-3\u2032-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog","volume":"35","author":"Soudeyns","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1073\/pnas.88.19.8495","article-title":"Inhibition of the replication of hepatitis B virus in vitro by 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine and related analogues","volume":"88","author":"Doong","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/AAC.36.4.733","article-title":"(-)-2\u2032-deoxy-3\u2032-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro","volume":"36","author":"Coates","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.36.1.202","article-title":"The separated enantiomers of 2\u2032-deoxy-3\u2032-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro","volume":"36","author":"Coates","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.36.3.672","article-title":"Activities of the four optical isomers of 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.37.10.2231","article-title":"High-level resistance to (-) enantiomeric 2\u2032-deoxy-3\u2032-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase","volume":"37","author":"Boucher","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","unstructured":"Stanford University (2022). Major Nucleoside RT Inhibitor (NRTI) Resistance Mutations. HIV Drug Resistance [Database Online], Stanford University. Available online: https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/NRTI."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1073\/pnas.86.13.4803","article-title":"Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity","volume":"86","author":"Larder","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1126\/science.7542804","article-title":"Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy","volume":"269","author":"Larder","year":"1995","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/095632020701800603","article-title":"The Balance between NRTI Discrimination and Excision Drives the Susceptibility of HIV-1 RT Mutants K65R, M184V and K65R+M184V","volume":"18","author":"Ly","year":"2007","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1128\/AAC.47.11.3478-3484.2003","article-title":"Tenofovir Resistance and Resensitization","volume":"47","author":"Wolf","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1093\/nar\/26.12.3066","article-title":"The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase","volume":"26","author":"Rezende","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1128\/jvi.70.7.4834-4838.1996","article-title":"Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human im-munodeficiency virus type 1 reverse transcriptase","volume":"70","author":"Drosopoulos","year":"1996","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","article-title":"Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study)","volume":"20","author":"Castagna","year":"2006","journal-title":"AIDS"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"CAESAR Coordinating Committee (1997). Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. Lancet, 349, 1413\u20131421.","DOI":"10.1016\/S0140-6736(97)04441-3"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3851\/IMP2650","article-title":"Implications of HIV drug resistance on first- and second-line therapies in resource-limited settings: Report from a workshop organized by the Collaborative HIV and Anti-HIV Drug Resistance Network","volume":"18","author":"Pillay","year":"2013","journal-title":"Antivir. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/hiv.12355","article-title":"Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-na\u00efve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort","volume":"17","author":"Rokx","year":"2016","journal-title":"HIV Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/00002030-200411190-00007","article-title":"A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV","volume":"18","author":"Benson","year":"2004","journal-title":"AIDS"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo-matched, multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment","volume":"23","author":"Smith","year":"2009","journal-title":"AIDS"},{"key":"ref_41","first-page":"1097","article-title":"Review of tenofovir-emtricitabine","volume":"3","author":"Masho","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpba.2011.05.039","article-title":"Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS\/MS detection","volume":"56","author":"Bushman","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/AAC.00816-06","article-title":"In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine","volume":"50","author":"Margot","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1310\/hct1202-61","article-title":"Reduced Emergence of the M184V\/I Resistance Mutation When Antiretroviral-Na\u00efve Subjects Use Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz","volume":"12","author":"McColl","year":"2011","journal-title":"HIV Clin. Trials"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/379667","article-title":"Prospective Randomized Trial of Emtricitabine versus Lamivudine Short-Term Monotherapy in Human Immunodeficiency Virus\u2013Infected Patients","volume":"188","author":"Rousseau","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ford, N., Shubber, Z., Hill, A., Vitoria, M., Doherty, M., Mills, E.J., and Gray, A. (2013). Comparative Efficacy of Lamivudine and Emtricitabine: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079981"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/cid\/ciu763","article-title":"Increased Virological Failure in Naive HIV-1-Infected Patients Taking Lamivudine Compared with Emtricitabine in Combination with Tenofovir and Efavirenz or Nevirapine in the Dutch Nationwide ATHENA Cohort","volume":"60","author":"Rokx","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/17425250903490418","article-title":"Lamivudine for the treatment of HIV","volume":"6","author":"Kumar","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/171.6.1411","article-title":"Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)","volume":"171","author":"Schuurman","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1086\/595296","article-title":"Sensitivity of Phenotypic Susceptibility Analyses for Nonthymidine Nucleoside Analogues Conferred by K65R or M184V in Mixtures with Wild-Type HIV","volume":"199","author":"Underwood","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/AAC.47.2.747-754.2003","article-title":"Lamivudine Can Exert a Modest Antiviral Effect against Human Immunodeficiency Virus Type 1 Containing the M184V Mutation","volume":"47","author":"Quan","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1128\/JVI.74.8.3579-3585.2000","article-title":"The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis","volume":"74","author":"Arion","year":"2000","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(00)80185-9","article-title":"A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase","volume":"4","author":"Meyer","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1586\/14787210.2.1.147","article-title":"The impact of the M184V substitution on drug resistance and viral fitness","volume":"2","author":"Wainberg","year":"2004","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_55","first-page":"223","article-title":"HIV-1 Fitness and Antiretroviral Drug Resistance","volume":"3","author":"Weber","year":"2001","journal-title":"AIDS Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/j.1460-2075.1996.tb00777.x","article-title":"Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme","volume":"15","author":"Back","year":"1996","journal-title":"EMBO J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.283.2.205","article-title":"Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients from a Trial of Induction-Maintenance Therapy","volume":"283","author":"Descamps","year":"2000","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00002030-199612005-00003","article-title":"The treatment of antiretroviral-naive subjects with the 3TC\/zidovudine combination: A review of North American (NUCA 3001) and European (NUCB 3001) trials","volume":"10","author":"Eron","year":"1996","journal-title":"AIDS"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/00002030-200006160-00017","article-title":"Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine\/lamivudine\/protease inhibitor combination therapy: Virological evaluation of the AVANTI 2 and AVANTI 3 studies","volume":"14","author":"Maguire","year":"2000","journal-title":"AIDS"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/135965350100600205","article-title":"Increased Drug Susceptibility of HIV-1 Reverse Transcriptase Mutants Containing M184V and Zidovudine-Associated Mutations: Analysis of Enzyme Processivity, Chain-Terminator Removal and Viral Replication","volume":"6","author":"Naeger","year":"2000","journal-title":"Antivir. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8448","DOI":"10.1128\/JVI.73.10.8448-8456.1999","article-title":"Decreased Processivity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Containing Didanosine-Selected Mutation Leu74Val: A Comparative Analysis of RT Variants Leu74Val and Lamivudine-Selected Met184Val","volume":"73","author":"Sharma","year":"1999","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1128\/AAC.05181-14","article-title":"Combination of the R263K and M184I\/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity","volume":"59","author":"Singhroy","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-4690-6-14","article-title":"Effects of the K65R and K65R\/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance","volume":"6","author":"Xu","year":"2009","journal-title":"Retrovirology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"16948","DOI":"10.1016\/S0021-9258(19)84799-3","article-title":"Specificity and Mechanism of Error-Prone Replication by Human Immunodeficiency Virus-1 Reverse Transcriptase","volume":"264","author":"Bebenek","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/jac\/dkr291","article-title":"Transmission dynamics of the M184V drug resistance mutation in primary HIV infection","volume":"66","author":"Wainberg","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00002030-199610090-00007","article-title":"Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients","volume":"10","author":"Kuritzkes","year":"1996","journal-title":"AIDS"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1468-1293.2002.00101.x","article-title":"The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response","volume":"3","author":"Miller","year":"2002","journal-title":"HIV Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/430709","article-title":"Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug-Resistant HIV-1 Infection","volume":"41","author":"Campbell","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_69","first-page":"224","article-title":"Might the M184V substitution in HIV-1 RT confer clinical benefit?","volume":"4","author":"Petrella","year":"2002","journal-title":"AIDS Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/infdis\/jix015","article-title":"Commonly transmitted HIV-1 drug resistance mutations in re-verse-transcriptase and protease in antiretroviral treatment\u2013naive patients and response to regimens containing tenofovir disoproxil fumarate or tenofovir alafenamide","volume":"215","author":"Margot","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1097\/QAD.0b013e3283121c90","article-title":"Transmission networks of drug resistance acquired in primary\/early stage HIV infection","volume":"22","author":"Brenner","year":"2008","journal-title":"AIDS"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","article-title":"HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study","volume":"11","author":"Hamers","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Rhee, S.Y., Jordan, M.R., Raizes, E., Chua, A., Parkin, N., Kantor, R., Van Zyl, G.U., Mukui, I., Hosseinipour, M.C., and Frenkel, L.M. (2015). HIV-1 drug resistance mutations: Potential applications for point-of-care genotypic resistance testing. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145772"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/cid\/cis254","article-title":"Patterns of HIV-1 Drug Resistance after First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies","volume":"54","author":"Hamers","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1089\/aid.2017.0205","article-title":"Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda","volume":"34","author":"Ndashimye","year":"2018","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_77","unstructured":"TenoRes Study Group (2016). Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study. Lancet Infect. Dis., 16, 565\u2013575."},{"key":"ref_78","unstructured":"HIV\/AIDS JUNPo (2018, October 25). Ending AIDS: Progress towards the 90-90-90 Targets. Global AIDS Update. Available online: https:\/\/unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_2017_ENDINGAIDS_Slides_en.pdf."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/cid\/ciz178","article-title":"Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients","volume":"70","author":"Abela","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_80","first-page":"281","article-title":"Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana","volume":"34","author":"Weiser","year":"2003","journal-title":"Am. J. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/427192","article-title":"Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy","volume":"191","author":"Harrigan","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Coetzee, J., Hunt, G., Jaffer, M., Otwombe, K., Scott, L., Bongwe, A., Ledwaba, J., Molema, S., Jewkes, R., and Gray, G.E. (2017). HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188606"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/jac\/dkw051","article-title":"HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults","volume":"71","author":"Hawkins","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/infdis\/jix544","article-title":"Prevalence of Pre-Antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013\u20132014","volume":"216","author":"Silverman","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Teto, G., Tagny, C.T., Mbanya, D., Fonsah, J.Y., Fokam, J., Nchindap, E., Kenmogne, L., Njamnshi, A.K., and Kanmogne, D. (2017). Gag P2\/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaound\u00e9, Cameroon. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-14095-4"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1097\/QAD.0000000000001110","article-title":"Increasing HIV-1 pretreatment drug resistance among antiretroviral-na\u00efve adults initiating treatment between 2006 and 2014 in Nairobi, Kenya","volume":"30","author":"Chung","year":"2016","journal-title":"AIDS"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/aid.2012.0167","article-title":"Low Prevalence of Transmitted HIV Type 1 Drug Resistance among Antiretroviral-Naive Adults in a Rural HIV Clinic in Kenya","volume":"29","author":"Hassan","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1128\/JCM.00634-17","article-title":"Multimethod longitudinal HIV drug resistance analysis in antiretroviral-therapy-naive patients","volume":"55","author":"Nanfack","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/aid.2012.0152","article-title":"Short communication: Prevalence of HIV type 1 transmitted drug resistance in Slovenia: 2005","volume":"29","author":"Lunar","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.meegid.2017.07.003","article-title":"Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003\u20132015: Transmitted drug resistance is due to onward transmissions","volume":"54","author":"Paraskevis","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.meegid.2016.12.019","article-title":"Differences in the integrase and reverse transcriptase transmitted resistance patterns in northern Poland","volume":"49","author":"Parczewski","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Pineda-Pe\u00f1a, A.-C., Schrooten, Y., Vinken, L., Ferreira, F., Li, G., Trov\u00e3o, N.S., Khouri, R., Derdelinckx, I., De Munter, P., and K\u00fccherer, C. (2014). Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101738"},{"key":"ref_93","first-page":"1328964","article-title":"Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996","volume":"7","author":"Sallam","year":"2017","journal-title":"Infect. Ecol. Epidemiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1089\/aid.2013.0270","article-title":"Ten years survey of primary HIV-1 resistance in Serbia: The occurrence of multiclass resistance","volume":"30","author":"Stanojevic","year":"2014","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hiv.12414","article-title":"Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom","volume":"18","author":"Tostevin","year":"2016","journal-title":"HIV Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Vega, Y., Delgado, E., Fern\u00e1ndez-Garc\u00eda, A., Cuevas, M.T., Thomson, M.M., Montero, V., S\u00e1nchez, M., S\u00e1nchez, A.M., P\u00e9rez-\u00c1lvarez, L., and Spanish Group for the Study of New HIV-1 Diagnoses in Galicia and Basque Country (2015). Epidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 2004\u20132012: Relevance of Transmission Clusters in the Propagation of Resistance Mutations. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125699"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1097\/QAD.0000000000000811","article-title":"Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals","volume":"29","author":"Winand","year":"2015","journal-title":"AIDS"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1089\/aid.2016.0159","article-title":"High HIV-1 Diversity and Prevalence of Transmitted Drug Resistance among Antiretroviral-Naive HIV-Infected Pregnant Women from Rio de Janeiro, Brazil","volume":"33","author":"Delatorre","year":"2017","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bjid.2017.03.013","article-title":"Transmitted drug resistance in patients with acute\/recent HIV infection in Brazil","volume":"21","author":"Ferreira","year":"2017","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/hiv.12122","article-title":"Community HIV-1 drug resistance is associated with transmitted drug resistance","volume":"15","author":"Tilghman","year":"2014","journal-title":"HIV Med."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Readhead, A.C., Gordon, D.E., Wang, Z., Anderson, B.J., Brousseau, K.S., Kouznetsova, M.A., Forgione, L.A., Smith, L.C., and Torian, L.V. (2012). Transmitted Antiretroviral Drug Resistance in New York State, 2006\u20132008: Results from a New Surveillance System. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040533"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Jiao, Y., Li, S., Li, Z., Zhang, Z., Zhao, J., Li, L., Wang, L., Yin, Q., Wang, Y., and Zeng, Z. (2014). HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-na\u00efve MSM from 2011 to 2013 in Beijing, China. BMC Infect. Dis., 14.","DOI":"10.1186\/s12879-014-0689-7"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Adawaye, C., Fokam, J., Kamangu, E., Alio, H.M., Chahad, A.M., Susin, F., Moussa, A.M., Bertin, T.H., Tidjani, A., and Vaira, D. (2017). Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N\u2019Djamena, Chad: Findings from a cross-sectional study. BMC Res. Notes, 10.","DOI":"10.1186\/s13104-017-2893-1"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa","volume":"71","author":"Boender","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"20798","DOI":"10.7448\/IAS.19.1.20798","article-title":"Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya","volume":"19","author":"Brooks","year":"2016","journal-title":"J. Int. AIDS Soc."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Van Zyl, G.U., Liu, T.F., Claassen, M., Engelbrecht, S., de Oliveira, T., Preiser, W., Wood, N.T., Travers, S., and Shafer, R.W. (2013). Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretro-Viral Treatment Regimens. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067188"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/QAD.0b013e32835b0f59","article-title":"Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy","volume":"27","author":"Etiebet","year":"2013","journal-title":"AIDS"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/aid.2011.0300","article-title":"High Rate Of Antiretroviral Drug Resistance Mutations in HIV Type 1-Infected Senegalese Children in Virological Failure on First-Line Treatment According to the World Health Organization Guidelines","volume":"29","author":"Kebe","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Namakoola, I., Kasamba, I., Mayanja, B.N., Kazooba, P., Lutaakome, J., Lyagoba, F., Kapaata, A.A., Kaleebu, P., Munderi, P., and On behalf of the CoLTART Study Team (2016). From antiretroviral therapy access to provision of third line regimens: Evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults. BMC Res. Notes, 9.","DOI":"10.1186\/s13104-016-2309-7"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/tmi.12717","article-title":"Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda","volume":"21","author":"Ndahimana","year":"2016","journal-title":"Trop. Med. Int. Health"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1099\/jmm.0.000621","article-title":"Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana","volume":"66","author":"Brandful","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-6405-11-3","article-title":"Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort","volume":"11","author":"Pillay","year":"2014","journal-title":"AIDS Res. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-6405-10-25","article-title":"Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic","volume":"10","author":"Sebunya","year":"2013","journal-title":"AIDS Res. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/aid.2014.0089","article-title":"Short Communication: Prevalence of HIV-1 Transmitted Drug Resistance in Liberia","volume":"30","author":"Loubet","year":"2014","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Skhosana, L., Steegen, K., Bronze, M., Lukhwareni, A., Letsoalo, E., Papathanasopoulos, M.A., Carmona, S.C., and Stevens, W.S. (2015). High Prevalence of the K65R Mutation in HIV-1 Subtype C Infected Patients Failing Tenofovir-Based First-Line Regimens in South Africa. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118145"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/jac\/dkw358","article-title":"HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: Results from a national survey in South Africa","volume":"72","author":"Steegen","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/aid.2011.0287","article-title":"Drug resistance mutations in HIV pol sequences from Argentinean patients under antiretroviral treatment: Subtype, gender, and age issues","volume":"28","author":"Jones","year":"2012","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"738528","DOI":"10.1155\/2015\/738528","article-title":"The Evolving Genotypic Profile of HIV-1 Mutations Related to Antiretroviral Treatment in the North Region of Brazil","volume":"2015","author":"Lopes","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"565","DOI":"10.5144\/0256-4947.2012.565","article-title":"Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy","volume":"32","author":"Frayha","year":"2012","journal-title":"Ann. Saudi Med."},{"key":"ref_120","first-page":"1256","article-title":"Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran","volume":"46","author":"Farrokhi","year":"2017","journal-title":"Iran. J. Public Health"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1097\/01.aids.0000386738.32919.67","article-title":"Assessing subtype and drug-resistance-associated mutations among antiretroviral-treated HIV-infected patients","volume":"24","author":"Hamkar","year":"2010","journal-title":"AIDS"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Charest, H., Doualla-Bell, F., Cantin, R., Murphy, D.G., Lemieux, L., Brenner, B., Hardy, I., Moisi, D., Lo, E., and Baril, J.G. (2014). A significant reduction in the frequency of HIV-1 drug resistance in Qu\u00e9bec from 2001 to 2011 is asso ciated with a decrease in the monitored viral load. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109420"},{"key":"ref_123","first-page":"246","article-title":"Temporal Patterns and Drug Resistance in CSF Viral Escape among ART-Experienced HIV-1 Infected Adults","volume":"75","author":"Mukerji","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3851\/IMP2771","article-title":"Prevalence in the Usa of Rilpivirine Resistance-Associated Mutations in Clinical Samples and Effects on Phenotypic Susceptibility to Rilpivirine and Etravirine","volume":"19","author":"Picchio","year":"2013","journal-title":"Antivir. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2147\/IDR.S158341","article-title":"Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: A multicenter cohort study","volume":"11","author":"Cheng","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/jac\/dku089","article-title":"Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea","volume":"69","author":"Gare","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Liu, P., Feng, Y., Wu, J., Tian, S., Su, B., Wang, Z., Liao, L., Xing, H., You, Y., and Shao, Y. (2017). Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV\/AIDS Patients Receiving Long-Term ART in China. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170139"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Ambrosioni, J., Sued, O., Nicolas, D., Parera, M., L\u00f3pez-Di\u00e9guez, M., Romero, A., Ag\u00fcero, F., Marcos, M.\u00c1., Manzardo, C., and Zamora, L. (2015). Trends in transmission of drug resistance and prevalence of bon-B subtypes in patients with acute or recent HIV-1 infection in Barcelona in the last 16 years (1997\u20132012). PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125837"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/jmv.24361","article-title":"Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia","volume":"88","author":"Avi","year":"2015","journal-title":"J. Med. Virol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir plus lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/jac\/dkt238","article-title":"National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001","volume":"68","author":"Descamps","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/jmv.23269","article-title":"Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia","volume":"84","author":"Dvali","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Frentz, D., Van de Vijver, D.A., Abecasis, A.B., Albert, J., Hamouda, O., J\u00f8rgensen, L.B., K\u00fccherer, C., Struck, D., Schmit, J.C., and Vercauteren, J. (2014). Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-407"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/cid\/civ963","article-title":"Transmission of HIV Drug Resistance and the Predicted Effect on Current First-Line Regimens in Europe","volume":"62","author":"Hofstra","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jmv.25245","article-title":"Epidemiology of HIV drug resistance in HIV patients with virologic failure of first-line therapy in the country of Georgia","volume":"91","author":"Karkashadze","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1089\/aid.2013.0108","article-title":"Transmission Network of an HIV Type 1 Strain with K103N in Young Belgian Patients from Different Risk Groups","volume":"29","author":"Ruelle","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_137","first-page":"12","article-title":"Long term nationwide analysis of HIV and AIDS in Iceland, 1983\u20132012","volume":"5","author":"Indridason","year":"2014","journal-title":"J. AIDS Clin. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.meegid.2013.06.015","article-title":"Molecular typing of the local HIV-1 epidemic in Serbia","volume":"19","author":"Siljic","year":"2013","journal-title":"Infect. Genet. Evol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e5253","DOI":"10.1136\/bmj.e5253","article-title":"Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: Multicentre observational study","volume":"345","author":"Dolling","year":"2012","journal-title":"BMJ"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350300800413","article-title":"High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: Study of genotypic resistance","volume":"8","author":"Carmona","year":"2003","journal-title":"Antivir. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.meegid.2007.01.009","article-title":"Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal","volume":"7","author":"Palma","year":"2007","journal-title":"Infect. Genet. Evol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1089\/aid.2012.0102","article-title":"Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States","volume":"29","author":"Menezes","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/327716a0","article-title":"Site-specific mutagenesis of AIDS virus reverse transcriptase","volume":"327","author":"Larder","year":"1987","journal-title":"Nature"},{"key":"ref_144","unstructured":"Stanford University HIV Drug Resistance Database (2024, July 24). DRM Penalty Scores and Resistance Interpretation. Available online: https:\/\/hivdb.stanford.edu\/page\/release-notes\/#drm.penalty.scores.and.resistance.interpretation."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/infdis\/jiz631","article-title":"Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals with Reverse-Transcriptase Mutation M184V\/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated with Compensatory Mutation L74I","volume":"222","author":"Gregson","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: Results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"Joly","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression through Week 48 in a Pilot Randomized Trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"21678","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J. Int. AIDS Soc."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferior","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/cid\/cix1083","article-title":"ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA < 500,000 copies\/mL","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Maggiolo, F., Gulminetti, R., Pagnucco, L., Digaetano, M., Benatti, S., Valenti, D., Callegaro, A., Ripamonti, D., and Mussini, C. (2017). Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2311-2"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: A planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living with Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study","volume":"71","author":"Ajana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/jiab413","article-title":"Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients","volume":"225","author":"Palich","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Black Americans with HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study","volume":"88","author":"Hagins","year":"2021","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_157","first-page":"705","article-title":"Bictegravir\/Emtricitabine\/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?","volume":"15","author":"Januszka","year":"2023","journal-title":"HIV AIDS"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"ofz330","DOI":"10.1093\/ofid\/ofz330","article-title":"Impact of the M184V\/I Mutation on the Efficacy of Abacavir\/Lamivudine\/Dolutegravir Therapy in HIV Treatment-Experienced Patients","volume":"6","author":"Olearo","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"De Miguel, R., Rial-Crestelo, D., Dominguez-Dominguez, L., Montejano, R., Esteban-Cantos, A., Aranguren-Rivas, P., Stella-Ascariz, N., Bisbal, O., Bermejo-Plaza, L., and Garcia-Alvarez, M. (2020). Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-Week results of a non-randomized, pilot clinical trial (ART-PRO). EBioMedicine, 55.","DOI":"10.1016\/j.ebiom.2020.102779"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"ofad526","DOI":"10.1093\/ofid\/ofad526","article-title":"Virologic Response to Dolutegravir Plus Lamivudine in People with Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V\/I: A Systematic Literature Review and Meta-Analysis","volume":"10","author":"Kabra","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijantimicag.2018.01.009","article-title":"Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations","volume":"51","author":"Carlander","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e16813","DOI":"10.1097\/MD.0000000000016813","article-title":"DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients","volume":"98","author":"Santos","year":"2019","journal-title":"Medicine"},{"key":"ref_163","unstructured":"Reynes, J., Meftah, N., Tuailon, E., Charpentier, C., and Montes, B. (2017, January 23\u201326). Dual regimen with Dolutegravir and Lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 Weeks results from maintenance DO-LULAM study. Proceedings of the 9th IAS Conference on HIV Science, Paris, France."},{"key":"ref_164","unstructured":"Pronier, C., Maillard, A., Comacle, P., Cameli, C., Rohan, J., and Jovelin, T. (2017, January 23\u201326). Successful switch to once-daily single-tablet regimen (STR) containing elvitegravir (EVG) or dolutegravir (DTG) in virologically suppressed HIV-1-infected patients despite archived resistant quasispecies. Proceedings of the 9th IAS Conference on HIV Science (IAS 2017), Paris, France."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jac\/dkaa019","article-title":"M184V\/I does not impact the efficacy of abacavir\/lamivudine\/dolutegravir use as switch therapy in virologically suppressed patients","volume":"75","author":"Jary","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): An open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"136","DOI":"10.24875\/AIDSRev.23000002","article-title":"The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: A systematic review and meta-analysis","volume":"25","author":"Kandeel","year":"2023","journal-title":"Aids Rev."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/jac\/dkw147","article-title":"Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine\/dolutegravir dual therapy","volume":"71","author":"Borghetti","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Capetti, A.F., Cossu, M.V., Orofino, G., Sterrantino, G., Cenderello, G., De Socio, G.V., Cattelan, A.M., Soria, A., Rusconi, S., and Riccardi, N. (2017). A dual regimen of ritonavir\/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 Weeks\u2019 observational data. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2755-4"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals with Suppressed HIV-1 RNA: A Cohort Study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Borghetti, A., Lombardi, F., Gagliardini, R., Baldin, G., Ciccullo, A., Moschese, D., Emiliozzi, A., Belmonti, S., Lamonica, S., and Montagnani, F. (2019). Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-018-3666-8"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2019.09.002","article-title":"Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients","volume":"54","author":"Baldin","year":"2019","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"105893","DOI":"10.1016\/j.ijantimicag.2020.105893","article-title":"Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients","volume":"55","author":"Galizzi","year":"2020","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/9\/1392\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:46:01Z","timestamp":1760111161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/9\/1392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":173,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["v16091392"],"URL":"https:\/\/doi.org\/10.3390\/v16091392","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}